
Molecular interactions underlying selective partitioning of clients into MED1 and FUS condensates: pnas.org/doi/10.1073/pnas.26…


Molecular interactions underlying selective partitioning of clients into MED1 and FUS condensates: pnas.org/doi/10.1073/pnas.26…

The NRF2-KEAP1 regulon is a transcriptional checkpoint for the NLRP3 inflammasome. Very pleased to share our study on how NRF2-KEAP1 links extracellular matrix sensing to NLRP3 regulation. Links to fibrosis, inflammation and cancer are presented. nature.com/articles/s41586-0…

Cancer drug resistance as a temporal process: cell plasticity, adaptive buffering, signaling pathways and therapeutic interception nature.com/articles/s41392-0…

the next generation of antibody–drug conjugates will require more than better payloads. a new review examines how antibody targeting, linker chemistry, drug loading, and tissue exposure collectively determine adc toxicity. improving the therapeutic window requires optimizing the entire molecular system. doi.org/10.1038/s41392-026-0…

what if we could degrade gpcrs instead of simply inhibiting them? a nature study describes a bifunctional antibody-based platform that rewires receptor trafficking to drive gpcr degradation and antagonism. an interesting expansion of targeted protein degradation beyond intracellular proteins. doi.org/10.1038/s41586-026-1…

Online Now: A TORC1-regulated H3K4me reader preserves promoter chromatin stability, and its degradation promotes meiotic remodeling dlvr.it/TWBQrF

Our latest research highlight covers a paper in Nature on the systematic design of bitopic kinase inhibitors nature.com/articles/d41573-0…

covalent drug discovery is moving beyond cysteine. new work in ACS chemical biology reports JL-03, a lys162-targeting eIF4E inhibitor using a vinyl acylsulfonamide electrophile. the interesting chemistry: the protein binding site helps activate the electrophile, enabling selective lysine modification. a compelling example of exploiting local protein microenvironments for covalent drug discovery. lifescience.net/publications…

Now out in Nature Cell Biology. Five labs brought quantitative proteomics, ribosome profiling, single-molecule imaging, preclinical models and patient-cohort analyses to bear on the unforeseen reach of the K55 dimethylation mark on elongation factor 1A. nature.com/articles/s41556-0…

Now online: hnRNPA2B1 sustains antitumor T cell immunity and enhances cancer immunotherapy through IDR-dependent stabilization of chromatin-regulatory transcripts doi.org/10.1158/2159-8290.CD…


Now online: H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer doi.org/10.1158/2159-8290.CD…

ONLINE NOW: Advances in modeling chromosomal aberrations to recapitulate genomic rearrangements dlvr.it/TVxlK7

Targeting protein arginine methyltransferases to enhance cancer immunotherapy dlvr.it/TVxTwG

Now online: KAT5 is Dual-Function Therapeutic Target with Direct Antitumor and Immunomodulatory Activity in Endometrial Cancer doi.org/10.1158/0008-5472.CA…

No short cut to learning - No AI can help you until YOU roll up the sleeves and read critically for yourself.
(One of the BEST ADCs review articles!) Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals J Hematol Oncol. 2025 Apr 30;18:51 pmc.ncbi.nlm.nih.gov/article…